The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.

Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the future of pharmaceutical advertising, health ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

The Food and Drug Administration announced that branded tirzepatide, the active ingredient in Eli Lilly's weight loss drug Zepbound, is no longer in short supply. That decision will largely ...